Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 204 | 2022 | 17569 | 8.150 |
Why?
|
Anti-HIV Agents | 83 | 2022 | 4573 | 6.780 |
Why?
|
AIDS Serodiagnosis | 20 | 2014 | 220 | 4.020 |
Why?
|
Cost-Benefit Analysis | 98 | 2022 | 5536 | 4.010 |
Why?
|
Penicillins | 10 | 2020 | 404 | 3.340 |
Why?
|
Anti-Retroviral Agents | 30 | 2021 | 1789 | 3.030 |
Why?
|
Mass Screening | 44 | 2020 | 5458 | 2.600 |
Why?
|
CD4 Lymphocyte Count | 50 | 2021 | 2596 | 2.570 |
Why?
|
South Africa | 59 | 2021 | 1873 | 2.270 |
Why?
|
Acquired Immunodeficiency Syndrome | 15 | 2022 | 2204 | 2.270 |
Why?
|
Drug Hypersensitivity | 11 | 2020 | 903 | 2.270 |
Why?
|
Drugs, Generic | 6 | 2022 | 455 | 2.010 |
Why?
|
Infectious Disease Transmission, Vertical | 12 | 2019 | 1354 | 1.840 |
Why?
|
Reagent Kits, Diagnostic | 7 | 2018 | 238 | 1.810 |
Why?
|
Infectious Disease Medicine | 3 | 2020 | 49 | 1.790 |
Why?
|
Antiretroviral Therapy, Highly Active | 25 | 2020 | 1903 | 1.780 |
Why?
|
Disease Transmission, Infectious | 7 | 2020 | 560 | 1.600 |
Why?
|
Models, Theoretical | 23 | 2020 | 3573 | 1.590 |
Why?
|
Computer Simulation | 35 | 2020 | 6283 | 1.570 |
Why?
|
Adenine | 8 | 2020 | 995 | 1.460 |
Why?
|
Life Expectancy | 29 | 2019 | 1248 | 1.460 |
Why?
|
HIV | 14 | 2021 | 1597 | 1.460 |
Why?
|
Tuberculosis | 16 | 2021 | 2029 | 1.440 |
Why?
|
Pneumonia, Viral | 8 | 2024 | 3238 | 1.370 |
Why?
|
Health Care Costs | 29 | 2020 | 3239 | 1.280 |
Why?
|
HIV Integrase Inhibitors | 4 | 2020 | 165 | 1.280 |
Why?
|
Staphylococcal Infections | 10 | 2018 | 1398 | 1.250 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 10 | 2018 | 704 | 1.230 |
Why?
|
Point-of-Care Systems | 7 | 2019 | 1238 | 1.210 |
Why?
|
Homosexuality, Male | 11 | 2022 | 1344 | 1.130 |
Why?
|
Coronavirus Infections | 7 | 2020 | 3115 | 1.120 |
Why?
|
Guidelines as Topic | 8 | 2021 | 1395 | 1.090 |
Why?
|
Heterocyclic Compounds, 3-Ring | 3 | 2019 | 296 | 1.070 |
Why?
|
Drug Monitoring | 5 | 2018 | 964 | 1.050 |
Why?
|
United States | 75 | 2023 | 73027 | 1.050 |
Why?
|
Measles | 4 | 2022 | 180 | 1.000 |
Why?
|
Humans | 296 | 2024 | 767991 | 0.990 |
Why?
|
Measles-Mumps-Rubella Vaccine | 4 | 2022 | 71 | 0.980 |
Why?
|
AIDS-Related Opportunistic Infections | 12 | 2016 | 664 | 0.980 |
Why?
|
Universities | 2 | 2020 | 1005 | 0.960 |
Why?
|
Job Satisfaction | 2 | 2019 | 548 | 0.940 |
Why?
|
Health Resources | 9 | 2019 | 950 | 0.940 |
Why?
|
Blood Donors | 2 | 2017 | 343 | 0.940 |
Why?
|
Public Health | 5 | 2023 | 2679 | 0.910 |
Why?
|
Anti-Bacterial Agents | 11 | 2021 | 7470 | 0.910 |
Why?
|
Civil Defense | 2 | 2023 | 115 | 0.900 |
Why?
|
Cross Infection | 6 | 2017 | 1426 | 0.890 |
Why?
|
Alanine | 3 | 2020 | 614 | 0.870 |
Why?
|
Communicable Disease Control | 5 | 2020 | 857 | 0.860 |
Why?
|
Benzoxazines | 5 | 2019 | 320 | 0.860 |
Why?
|
Diagnostic Tests, Routine | 7 | 2020 | 788 | 0.850 |
Why?
|
Drug Costs | 13 | 2020 | 1195 | 0.850 |
Why?
|
Adult | 151 | 2023 | 223583 | 0.840 |
Why?
|
Drug Approval | 2 | 2020 | 820 | 0.840 |
Why?
|
Smoking Cessation | 3 | 2020 | 2085 | 0.790 |
Why?
|
Smallpox Vaccine | 1 | 2022 | 77 | 0.780 |
Why?
|
Pandemics | 9 | 2020 | 8748 | 0.780 |
Why?
|
Male | 162 | 2024 | 364641 | 0.730 |
Why?
|
Faculty, Medical | 3 | 2019 | 1225 | 0.730 |
Why?
|
World Health Organization | 8 | 2014 | 1328 | 0.720 |
Why?
|
Costs and Cost Analysis | 5 | 2020 | 1666 | 0.720 |
Why?
|
Chemoprevention | 4 | 2014 | 327 | 0.710 |
Why?
|
Infection Control | 5 | 2017 | 985 | 0.710 |
Why?
|
Medically Uninsured | 2 | 2023 | 840 | 0.700 |
Why?
|
Viral Load | 9 | 2018 | 3396 | 0.700 |
Why?
|
Communicable Diseases | 2 | 2020 | 874 | 0.700 |
Why?
|
Quality-Adjusted Life Years | 16 | 2021 | 1741 | 0.700 |
Why?
|
HIV Seropositivity | 4 | 2015 | 966 | 0.700 |
Why?
|
Drug Resistance, Viral | 9 | 2020 | 869 | 0.700 |
Why?
|
Reverse Transcriptase Inhibitors | 8 | 2020 | 620 | 0.690 |
Why?
|
Female | 165 | 2022 | 397113 | 0.690 |
Why?
|
Models, Biological | 17 | 2019 | 9493 | 0.680 |
Why?
|
Voluntary Programs | 4 | 2014 | 48 | 0.670 |
Why?
|
Bacteriological Techniques | 4 | 2014 | 277 | 0.670 |
Why?
|
Emergency Service, Hospital | 10 | 2013 | 7939 | 0.670 |
Why?
|
Insurance, Health | 2 | 2023 | 2517 | 0.670 |
Why?
|
HIV-1 | 18 | 2017 | 6960 | 0.670 |
Why?
|
Immunization Programs | 2 | 2020 | 267 | 0.670 |
Why?
|
Counseling | 11 | 2014 | 1554 | 0.670 |
Why?
|
Sentinel Surveillance | 2 | 2015 | 292 | 0.660 |
Why?
|
Models, Economic | 12 | 2020 | 719 | 0.650 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.640 |
Why?
|
Clinical Trials as Topic | 13 | 2021 | 8052 | 0.630 |
Why?
|
Vaccination | 6 | 2023 | 3437 | 0.630 |
Why?
|
Bacteremia | 2 | 2016 | 986 | 0.620 |
Why?
|
Patient Acceptance of Health Care | 12 | 2014 | 3231 | 0.620 |
Why?
|
Clinical Laboratory Techniques | 5 | 2020 | 746 | 0.610 |
Why?
|
Quarantine | 1 | 2020 | 186 | 0.600 |
Why?
|
Masks | 1 | 2020 | 214 | 0.600 |
Why?
|
Hospitals, General | 3 | 2018 | 806 | 0.590 |
Why?
|
Budgets | 3 | 2020 | 232 | 0.580 |
Why?
|
Disaster Planning | 1 | 2023 | 559 | 0.550 |
Why?
|
Sensitivity and Specificity | 24 | 2021 | 14718 | 0.550 |
Why?
|
Lipopolysaccharides | 3 | 2021 | 2219 | 0.540 |
Why?
|
Biomedical Research | 3 | 2017 | 3463 | 0.540 |
Why?
|
Models, Statistical | 9 | 2019 | 5107 | 0.540 |
Why?
|
Occupational Diseases | 2 | 2020 | 1457 | 0.530 |
Why?
|
Cost Sharing | 1 | 2020 | 409 | 0.530 |
Why?
|
Drug Substitution | 2 | 2018 | 291 | 0.520 |
Why?
|
Treatment Refusal | 3 | 2017 | 433 | 0.520 |
Why?
|
RNA, Viral | 11 | 2018 | 2871 | 0.520 |
Why?
|
International Cooperation | 3 | 2022 | 1434 | 0.510 |
Why?
|
Middle Aged | 86 | 2021 | 223422 | 0.510 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2227 | 0.510 |
Why?
|
Rubella | 3 | 2022 | 55 | 0.500 |
Why?
|
Health Services Accessibility | 8 | 2023 | 5520 | 0.490 |
Why?
|
Medicare Part D | 1 | 2020 | 355 | 0.490 |
Why?
|
Catheter-Related Infections | 2 | 2015 | 275 | 0.490 |
Why?
|
Mumps | 3 | 2022 | 71 | 0.480 |
Why?
|
Vaccines | 1 | 2023 | 842 | 0.470 |
Why?
|
Nevirapine | 5 | 2015 | 273 | 0.470 |
Why?
|
Mentors | 2 | 2018 | 671 | 0.470 |
Why?
|
Organizational Policy | 2 | 2017 | 435 | 0.460 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2019 | 843 | 0.460 |
Why?
|
Sex Factors | 7 | 2019 | 10627 | 0.460 |
Why?
|
Lamivudine | 1 | 2015 | 367 | 0.460 |
Why?
|
Gram-Positive Bacterial Infections | 3 | 2014 | 342 | 0.450 |
Why?
|
Forecasting | 5 | 2019 | 2945 | 0.450 |
Why?
|
Health Personnel | 4 | 2020 | 3385 | 0.450 |
Why?
|
Continuity of Patient Care | 6 | 2017 | 1078 | 0.450 |
Why?
|
Insurance Coverage | 3 | 2023 | 1946 | 0.440 |
Why?
|
Young Adult | 41 | 2024 | 60048 | 0.440 |
Why?
|
Rheumatic Diseases | 1 | 2020 | 659 | 0.430 |
Why?
|
Drug Industry | 1 | 2020 | 791 | 0.430 |
Why?
|
Medical Assistance | 3 | 2010 | 108 | 0.430 |
Why?
|
Influenza, Human | 1 | 2024 | 1541 | 0.420 |
Why?
|
Refusal to Participate | 1 | 2013 | 30 | 0.420 |
Why?
|
Smoking | 4 | 2020 | 9089 | 0.410 |
Why?
|
HIV Seroprevalence | 2 | 2011 | 89 | 0.410 |
Why?
|
Research Support as Topic | 2 | 2014 | 696 | 0.400 |
Why?
|
Refugees | 5 | 2020 | 615 | 0.400 |
Why?
|
Skin Tests | 4 | 2020 | 630 | 0.400 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.400 |
Why?
|
Breast Feeding | 4 | 2018 | 1363 | 0.390 |
Why?
|
Urinary Tract Infections | 2 | 2015 | 804 | 0.390 |
Why?
|
Academic Medical Centers | 4 | 2020 | 2783 | 0.390 |
Why?
|
Lost to Follow-Up | 4 | 2020 | 124 | 0.380 |
Why?
|
Sputum | 6 | 2021 | 516 | 0.380 |
Why?
|
Biological Products | 1 | 2020 | 948 | 0.370 |
Why?
|
Career Choice | 1 | 2017 | 769 | 0.360 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2014 | 794 | 0.360 |
Why?
|
Cote d'Ivoire | 8 | 2019 | 65 | 0.360 |
Why?
|
Drug Utilization | 1 | 2017 | 1190 | 0.360 |
Why?
|
Basic Reproduction Number | 2 | 2020 | 38 | 0.360 |
Why?
|
HIV Protease Inhibitors | 4 | 2013 | 430 | 0.360 |
Why?
|
Preventive Health Services | 2 | 2013 | 570 | 0.350 |
Why?
|
Health Expenditures | 2 | 2020 | 2389 | 0.350 |
Why?
|
Allergens | 2 | 2017 | 1434 | 0.350 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1381 | 0.340 |
Why?
|
Risk-Taking | 7 | 2020 | 1023 | 0.340 |
Why?
|
India | 8 | 2020 | 2334 | 0.340 |
Why?
|
Government Programs | 3 | 2010 | 278 | 0.330 |
Why?
|
Patient Isolation | 2 | 2020 | 101 | 0.330 |
Why?
|
Alkynes | 5 | 2019 | 326 | 0.320 |
Why?
|
Mobile Health Units | 3 | 2015 | 93 | 0.320 |
Why?
|
Ambulatory Care Facilities | 7 | 2019 | 939 | 0.320 |
Why?
|
Enterococcus | 3 | 2017 | 159 | 0.320 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2012 | 944 | 0.310 |
Why?
|
Cyclopropanes | 5 | 2019 | 436 | 0.310 |
Why?
|
Health Policy | 4 | 2020 | 2698 | 0.310 |
Why?
|
State Government | 2 | 2011 | 388 | 0.300 |
Why?
|
Sexual Behavior | 7 | 2017 | 2197 | 0.300 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1430 | 0.300 |
Why?
|
Toxoplasmosis | 1 | 2008 | 94 | 0.300 |
Why?
|
Antiviral Agents | 1 | 2020 | 3073 | 0.300 |
Why?
|
Diagnostic Services | 1 | 2007 | 33 | 0.300 |
Why?
|
Physicians | 2 | 2020 | 4598 | 0.290 |
Why?
|
Prevalence | 25 | 2020 | 15867 | 0.290 |
Why?
|
Informed Consent | 2 | 2011 | 1010 | 0.290 |
Why?
|
Cohort Studies | 30 | 2020 | 41749 | 0.290 |
Why?
|
Adolescent | 37 | 2021 | 89155 | 0.280 |
Why?
|
Boston | 11 | 2020 | 9368 | 0.280 |
Why?
|
Computers | 1 | 2010 | 592 | 0.280 |
Why?
|
Resource Allocation | 3 | 2009 | 354 | 0.280 |
Why?
|
Oxazines | 3 | 2019 | 358 | 0.280 |
Why?
|
Methicillin | 2 | 2017 | 62 | 0.270 |
Why?
|
Delivery of Health Care | 4 | 2020 | 5366 | 0.270 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9252 | 0.270 |
Why?
|
Case Management | 1 | 2008 | 277 | 0.270 |
Why?
|
Pregnancy | 16 | 2021 | 30260 | 0.270 |
Why?
|
Kaposi Varicelliform Eruption | 1 | 2006 | 47 | 0.270 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.260 |
Why?
|
Drug Administration Schedule | 6 | 2020 | 4857 | 0.260 |
Why?
|
Patient Transfer | 3 | 2019 | 790 | 0.260 |
Why?
|
Truth Disclosure | 1 | 2010 | 434 | 0.260 |
Why?
|
HIV Fusion Inhibitors | 2 | 2006 | 82 | 0.250 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1798 | 0.250 |
Why?
|
Aged | 30 | 2021 | 171446 | 0.250 |
Why?
|
Internship and Residency | 5 | 2017 | 5952 | 0.250 |
Why?
|
History, 21st Century | 2 | 2024 | 1572 | 0.240 |
Why?
|
Survival Analysis | 12 | 2019 | 10098 | 0.240 |
Why?
|
Treatment Outcome | 25 | 2020 | 65364 | 0.240 |
Why?
|
HIV-2 | 3 | 2012 | 156 | 0.240 |
Why?
|
Immunotherapy, Active | 1 | 2004 | 58 | 0.230 |
Why?
|
Risk Assessment | 6 | 2021 | 24314 | 0.230 |
Why?
|
Practice Guidelines as Topic | 6 | 2017 | 7445 | 0.230 |
Why?
|
Incidence | 13 | 2021 | 21532 | 0.230 |
Why?
|
Africa South of the Sahara | 7 | 2017 | 752 | 0.230 |
Why?
|
Antibodies, Heterophile | 2 | 2001 | 128 | 0.230 |
Why?
|
HIV Envelope Protein gp41 | 2 | 2006 | 306 | 0.230 |
Why?
|
Infectious Mononucleosis | 2 | 2001 | 133 | 0.230 |
Why?
|
Self Care | 1 | 2009 | 799 | 0.230 |
Why?
|
Needlestick Injuries | 1 | 2004 | 71 | 0.230 |
Why?
|
Government Regulation | 2 | 2020 | 525 | 0.220 |
Why?
|
Pyridones | 3 | 2019 | 819 | 0.220 |
Why?
|
Outpatients | 4 | 2021 | 1600 | 0.220 |
Why?
|
Vancomycin | 2 | 2017 | 504 | 0.220 |
Why?
|
Program Evaluation | 5 | 2015 | 2506 | 0.220 |
Why?
|
Interviews as Topic | 2 | 2012 | 2741 | 0.210 |
Why?
|
AIDS Vaccines | 2 | 2012 | 900 | 0.210 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13499 | 0.210 |
Why?
|
Prisoners | 1 | 2006 | 316 | 0.210 |
Why?
|
Decision Support Techniques | 5 | 2017 | 2008 | 0.210 |
Why?
|
History, 20th Century | 2 | 2024 | 2766 | 0.210 |
Why?
|
Public Health Administration | 2 | 2021 | 242 | 0.210 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2021 | 339 | 0.210 |
Why?
|
Injections, Intradermal | 1 | 2022 | 116 | 0.200 |
Why?
|
Microbial Sensitivity Tests | 4 | 2016 | 1967 | 0.200 |
Why?
|
Risk Factors | 24 | 2023 | 74936 | 0.200 |
Why?
|
Monkeypox virus | 1 | 2022 | 43 | 0.200 |
Why?
|
Smallpox | 1 | 2022 | 43 | 0.200 |
Why?
|
Travel | 2 | 2020 | 805 | 0.200 |
Why?
|
Early Diagnosis | 5 | 2020 | 1193 | 0.200 |
Why?
|
Isoniazid | 4 | 2016 | 288 | 0.200 |
Why?
|
Vancomycin Resistance | 2 | 2012 | 125 | 0.190 |
Why?
|
Exanthema | 1 | 2006 | 502 | 0.190 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2011 | 2185 | 0.190 |
Why?
|
United States Food and Drug Administration | 4 | 2021 | 1671 | 0.190 |
Why?
|
Osteoarthritis, Knee | 4 | 2015 | 1251 | 0.190 |
Why?
|
Aged, 80 and over | 13 | 2021 | 59598 | 0.190 |
Why?
|
Delayed-Action Preparations | 2 | 2015 | 968 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.180 |
Why?
|
Drug Therapy, Combination | 6 | 2012 | 6314 | 0.180 |
Why?
|
Hospitals, Urban | 3 | 2012 | 496 | 0.180 |
Why?
|
Reproducibility of Results | 7 | 2019 | 20218 | 0.180 |
Why?
|
Massachusetts | 6 | 2018 | 8888 | 0.180 |
Why?
|
Ambulatory Care | 5 | 2017 | 2781 | 0.180 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2024 | 452 | 0.180 |
Why?
|
Malawi | 2 | 2019 | 312 | 0.180 |
Why?
|
Inpatients | 4 | 2020 | 2570 | 0.180 |
Why?
|
Dideoxynucleosides | 2 | 2008 | 135 | 0.180 |
Why?
|
Cough | 1 | 2024 | 598 | 0.170 |
Why?
|
Genotype | 6 | 2020 | 13042 | 0.170 |
Why?
|
Drug Combinations | 2 | 2019 | 2089 | 0.170 |
Why?
|
Health Education | 2 | 2020 | 1059 | 0.170 |
Why?
|
Albendazole | 1 | 2020 | 51 | 0.170 |
Why?
|
Cross-Sectional Studies | 10 | 2021 | 26375 | 0.170 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2020 | 52 | 0.170 |
Why?
|
Gastrointestinal Diseases | 1 | 2008 | 1207 | 0.170 |
Why?
|
Health Care Rationing | 2 | 2017 | 435 | 0.170 |
Why?
|
Pyrimethamine | 1 | 2020 | 95 | 0.170 |
Why?
|
Calibration | 2 | 2020 | 819 | 0.170 |
Why?
|
Patient Satisfaction | 2 | 2012 | 3488 | 0.170 |
Why?
|
Infant | 16 | 2022 | 36534 | 0.170 |
Why?
|
Ritonavir | 3 | 2015 | 331 | 0.160 |
Why?
|
Texas | 1 | 2020 | 410 | 0.160 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 404 | 0.160 |
Why?
|
Recurrence | 3 | 2020 | 8507 | 0.150 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2012 | 337 | 0.150 |
Why?
|
Piperazines | 3 | 2019 | 2552 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 212 | 0.150 |
Why?
|
Infant Care | 1 | 2019 | 182 | 0.150 |
Why?
|
Time Factors | 15 | 2018 | 40214 | 0.150 |
Why?
|
Health Plan Implementation | 1 | 2021 | 338 | 0.150 |
Why?
|
Prospective Studies | 19 | 2019 | 54924 | 0.150 |
Why?
|
Referral and Consultation | 4 | 2017 | 3619 | 0.150 |
Why?
|
Gynecology | 2 | 2014 | 534 | 0.150 |
Why?
|
Radiography, Thoracic | 1 | 2024 | 1321 | 0.150 |
Why?
|
False Negative Reactions | 2 | 2011 | 571 | 0.150 |
Why?
|
Zidovudine | 3 | 2015 | 625 | 0.140 |
Why?
|
Financing, Government | 2 | 2014 | 473 | 0.140 |
Why?
|
Chest Pain | 1 | 2024 | 1101 | 0.140 |
Why?
|
Community Health Services | 2 | 2013 | 659 | 0.140 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6071 | 0.140 |
Why?
|
Antitubercular Agents | 3 | 2020 | 1397 | 0.140 |
Why?
|
Postnatal Care | 1 | 2019 | 273 | 0.140 |
Why?
|
Capital Financing | 1 | 2017 | 58 | 0.140 |
Why?
|
Blood Safety | 1 | 2016 | 16 | 0.140 |
Why?
|
Influenza Vaccines | 1 | 2024 | 780 | 0.140 |
Why?
|
Vulnerable Populations | 2 | 2020 | 718 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2019 | 10396 | 0.140 |
Why?
|
Fever | 1 | 2024 | 1613 | 0.140 |
Why?
|
Neural Tube Defects | 1 | 2019 | 255 | 0.140 |
Why?
|
Infant, Newborn | 12 | 2020 | 26420 | 0.140 |
Why?
|
Pseudomyxoma Peritonei | 1 | 1996 | 21 | 0.140 |
Why?
|
Obstetrics | 2 | 2014 | 681 | 0.140 |
Why?
|
Dyspnea | 1 | 2024 | 1352 | 0.130 |
Why?
|
Social Behavior | 2 | 2021 | 1147 | 0.130 |
Why?
|
Hospitals | 5 | 2020 | 3886 | 0.130 |
Why?
|
Deoxycytidine | 2 | 2013 | 887 | 0.130 |
Why?
|
Amoxicillin | 1 | 2017 | 181 | 0.130 |
Why?
|
Retrospective Studies | 11 | 2021 | 81746 | 0.130 |
Why?
|
Urban Population | 4 | 2017 | 2045 | 0.130 |
Why?
|
Pyrimidinones | 2 | 2011 | 386 | 0.130 |
Why?
|
Cephalosporins | 1 | 2017 | 200 | 0.130 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.130 |
Why?
|
HIV Reverse Transcriptase | 2 | 2009 | 214 | 0.130 |
Why?
|
Career Mobility | 1 | 2018 | 262 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4423 | 0.130 |
Why?
|
Uganda | 5 | 2020 | 1361 | 0.130 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.130 |
Why?
|
Methicillin Resistance | 2 | 2015 | 198 | 0.130 |
Why?
|
Disease Outbreaks | 2 | 2023 | 1761 | 0.130 |
Why?
|
Anti-Infective Agents | 3 | 2009 | 983 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2014 | 4055 | 0.120 |
Why?
|
Ethambutol | 2 | 2012 | 59 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 3929 | 0.120 |
Why?
|
Developing Countries | 5 | 2011 | 2913 | 0.120 |
Why?
|
Public Sector | 1 | 2017 | 266 | 0.120 |
Why?
|
Demography | 3 | 2015 | 1641 | 0.120 |
Why?
|
Disease Progression | 9 | 2013 | 13665 | 0.120 |
Why?
|
Nicotine | 1 | 2020 | 680 | 0.120 |
Why?
|
Decision Trees | 2 | 2009 | 508 | 0.120 |
Why?
|
Africa | 2 | 2014 | 725 | 0.120 |
Why?
|
Epidemics | 1 | 2021 | 517 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 12252 | 0.120 |
Why?
|
Treatment Failure | 3 | 2014 | 2660 | 0.120 |
Why?
|
Gender Identity | 1 | 2021 | 770 | 0.120 |
Why?
|
Device Approval | 2 | 2006 | 164 | 0.120 |
Why?
|
Brazil | 2 | 2016 | 1250 | 0.120 |
Why?
|
Child | 17 | 2022 | 80906 | 0.120 |
Why?
|
beta-Lactams | 1 | 2016 | 158 | 0.120 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1406 | 0.120 |
Why?
|
Cause of Death | 2 | 2021 | 3720 | 0.120 |
Why?
|
Circumcision, Male | 1 | 2016 | 148 | 0.120 |
Why?
|
Intensive Care Units | 2 | 2020 | 3800 | 0.120 |
Why?
|
Air | 1 | 2014 | 186 | 0.110 |
Why?
|
Zimbabwe | 4 | 2019 | 135 | 0.110 |
Why?
|
Pyrrolidinones | 1 | 2014 | 116 | 0.110 |
Why?
|
Condoms | 1 | 2016 | 337 | 0.110 |
Why?
|
Documentation | 1 | 2020 | 917 | 0.110 |
Why?
|
Population Surveillance | 3 | 2021 | 2594 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2006 | 5151 | 0.110 |
Why?
|
Gross Domestic Product | 1 | 2013 | 77 | 0.110 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2015 | 1389 | 0.110 |
Why?
|
HIV Antibodies | 3 | 2012 | 1341 | 0.110 |
Why?
|
Geographic Information Systems | 1 | 2015 | 283 | 0.110 |
Why?
|
Medically Underserved Area | 1 | 2015 | 268 | 0.110 |
Why?
|
Diagnostic Test Approval | 1 | 2012 | 3 | 0.110 |
Why?
|
Patient Compliance | 5 | 2017 | 2697 | 0.110 |
Why?
|
Age Factors | 5 | 2013 | 18407 | 0.110 |
Why?
|
Infant Mortality | 1 | 2018 | 752 | 0.100 |
Why?
|
Internal Medicine | 1 | 2020 | 1064 | 0.100 |
Why?
|
Standard of Care | 1 | 2017 | 568 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2018 | 12075 | 0.100 |
Why?
|
Professional Competence | 1 | 2015 | 430 | 0.100 |
Why?
|
Mycobacterium tuberculosis | 3 | 2014 | 1930 | 0.100 |
Why?
|
Bone Diseases | 1 | 2015 | 416 | 0.100 |
Why?
|
Anaphylaxis | 1 | 1999 | 755 | 0.100 |
Why?
|
Cost Savings | 2 | 2015 | 904 | 0.100 |
Why?
|
False Positive Reactions | 2 | 2006 | 962 | 0.100 |
Why?
|
Contact Tracing | 1 | 2014 | 275 | 0.090 |
Why?
|
Risk | 4 | 2017 | 9609 | 0.090 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 195 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2018 | 562 | 0.090 |
Why?
|
Substance Abuse Treatment Centers | 1 | 2012 | 155 | 0.090 |
Why?
|
Models, Econometric | 2 | 2013 | 215 | 0.090 |
Why?
|
Immunoglobulin E | 1 | 2017 | 1497 | 0.090 |
Why?
|
Health Care Surveys | 3 | 2017 | 2433 | 0.090 |
Why?
|
Glucocorticoids | 1 | 2020 | 2166 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2021 | 1188 | 0.090 |
Why?
|
Goals | 1 | 2016 | 717 | 0.090 |
Why?
|
Mortality | 2 | 2019 | 2910 | 0.090 |
Why?
|
Adrenal Glands | 1 | 2013 | 557 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 635 | 0.090 |
Why?
|
Nasal Mucosa | 1 | 2014 | 416 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2013 | 4415 | 0.090 |
Why?
|
Emergency Medical Services | 2 | 2012 | 1947 | 0.090 |
Why?
|
District of Columbia | 1 | 2010 | 159 | 0.090 |
Why?
|
Teratogens | 1 | 2011 | 119 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3813 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13289 | 0.090 |
Why?
|
Age Distribution | 3 | 2011 | 2871 | 0.090 |
Why?
|
Students | 1 | 2020 | 1744 | 0.090 |
Why?
|
Child, Preschool | 9 | 2022 | 42665 | 0.090 |
Why?
|
Carrier State | 1 | 2014 | 529 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2013 | 7851 | 0.090 |
Why?
|
Social Stigma | 2 | 2021 | 788 | 0.080 |
Why?
|
Peritoneal Neoplasms | 1 | 1996 | 707 | 0.080 |
Why?
|
Prospective Payment System | 1 | 2010 | 134 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 2 | 2014 | 668 | 0.080 |
Why?
|
Health Services | 2 | 2012 | 755 | 0.080 |
Why?
|
Family | 1 | 2020 | 3210 | 0.080 |
Why?
|
Health Services Research | 1 | 2017 | 1815 | 0.080 |
Why?
|
Emigration and Immigration | 1 | 2012 | 406 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 13000 | 0.080 |
Why?
|
Cities | 1 | 2011 | 543 | 0.080 |
Why?
|
Rural Population | 2 | 2017 | 2325 | 0.080 |
Why?
|
Hospital Administration | 1 | 2012 | 351 | 0.080 |
Why?
|
Bottle Feeding | 1 | 2008 | 67 | 0.080 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 2473 | 0.080 |
Why?
|
Homosexuality | 1 | 2009 | 269 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2009 | 202 | 0.080 |
Why?
|
Mathematics | 1 | 2009 | 704 | 0.070 |
Why?
|
Educational Status | 2 | 2013 | 2515 | 0.070 |
Why?
|
Hypothalamus | 1 | 2013 | 1004 | 0.070 |
Why?
|
Morbidity | 1 | 2013 | 1754 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 618 | 0.070 |
Why?
|
Prejudice | 2 | 2012 | 574 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1942 | 0.070 |
Why?
|
Saliva | 1 | 2012 | 853 | 0.070 |
Why?
|
Research | 1 | 2016 | 1979 | 0.070 |
Why?
|
Fractures, Bone | 1 | 2020 | 2062 | 0.070 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1698 | 0.070 |
Why?
|
Medicaid | 1 | 2021 | 2840 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2496 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2756 | 0.070 |
Why?
|
Acanthamoeba | 1 | 2006 | 12 | 0.070 |
Why?
|
HLA-B Antigens | 1 | 2008 | 330 | 0.070 |
Why?
|
Amebiasis | 1 | 2006 | 33 | 0.070 |
Why?
|
Thrombosis | 1 | 2021 | 2957 | 0.070 |
Why?
|
Income | 2 | 2013 | 1878 | 0.070 |
Why?
|
Interpersonal Relations | 1 | 2014 | 1434 | 0.070 |
Why?
|
Data Collection | 2 | 2012 | 3326 | 0.070 |
Why?
|
Research Design | 2 | 2020 | 6211 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 15442 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2012 | 1474 | 0.060 |
Why?
|
Urban Health | 1 | 2008 | 534 | 0.060 |
Why?
|
Quality of Life | 6 | 2017 | 13489 | 0.060 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1178 | 0.060 |
Why?
|
Lung | 1 | 2024 | 10094 | 0.060 |
Why?
|
Herpesvirus 4, Human | 2 | 2001 | 1082 | 0.060 |
Why?
|
Hospitalization | 4 | 2020 | 10840 | 0.060 |
Why?
|
State Health Plans | 2 | 2009 | 220 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2007 | 392 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6228 | 0.060 |
Why?
|
Hospital Costs | 1 | 2011 | 957 | 0.060 |
Why?
|
Patient Preference | 1 | 2012 | 946 | 0.060 |
Why?
|
Patient Admission | 1 | 2012 | 1365 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2100 | 0.060 |
Why?
|
Antibodies, Viral | 2 | 2010 | 3216 | 0.060 |
Why?
|
Antifungal Agents | 1 | 2010 | 761 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3837 | 0.060 |
Why?
|
Granuloma | 1 | 2006 | 329 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1982 | 0.060 |
Why?
|
Pilot Projects | 4 | 2018 | 8740 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1883 | 0.060 |
Why?
|
Hospitals, Teaching | 2 | 2015 | 1157 | 0.060 |
Why?
|
Length of Stay | 2 | 2016 | 6495 | 0.060 |
Why?
|
Investments | 1 | 2005 | 149 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1804 | 0.050 |
Why?
|
Blotting, Western | 1 | 2011 | 5024 | 0.050 |
Why?
|
Research Personnel | 1 | 2008 | 589 | 0.050 |
Why?
|
Urinalysis | 2 | 2016 | 370 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2006 | 1259 | 0.050 |
Why?
|
Survival Rate | 3 | 2012 | 12828 | 0.050 |
Why?
|
Encephalitis | 1 | 2006 | 441 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6809 | 0.050 |
Why?
|
Virology | 2 | 2017 | 76 | 0.050 |
Why?
|
Physicians, Women | 1 | 2008 | 516 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3433 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2708 | 0.050 |
Why?
|
Psychiatry | 1 | 2014 | 1716 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2420 | 0.050 |
Why?
|
Terminology as Topic | 1 | 2008 | 1542 | 0.050 |
Why?
|
Hypertension | 2 | 2019 | 8616 | 0.050 |
Why?
|
Health Behavior | 1 | 2012 | 2650 | 0.050 |
Why?
|
Pharmaceutical Services | 1 | 2002 | 143 | 0.050 |
Why?
|
Financial Management | 1 | 2002 | 161 | 0.040 |
Why?
|
Immunity, Herd | 1 | 2020 | 48 | 0.040 |
Why?
|
Curriculum | 1 | 2014 | 3782 | 0.040 |
Why?
|
Patient Simulation | 1 | 2002 | 297 | 0.040 |
Why?
|
Latent Tuberculosis | 2 | 2014 | 224 | 0.040 |
Why?
|
Acute Disease | 1 | 2011 | 7241 | 0.040 |
Why?
|
France | 2 | 2012 | 497 | 0.040 |
Why?
|
Interinstitutional Relations | 1 | 2021 | 235 | 0.040 |
Why?
|
Hepatitis C | 1 | 2010 | 1594 | 0.040 |
Why?
|
Probability | 1 | 2005 | 2479 | 0.040 |
Why?
|
Family Characteristics | 2 | 2015 | 1003 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2018 | 3435 | 0.040 |
Why?
|
Geography | 2 | 2013 | 652 | 0.040 |
Why?
|
Odds Ratio | 3 | 2021 | 9666 | 0.040 |
Why?
|
Fellowships and Scholarships | 1 | 2008 | 1135 | 0.040 |
Why?
|
Regression Analysis | 3 | 2016 | 6339 | 0.040 |
Why?
|
Hydrocortisone | 1 | 2006 | 1840 | 0.040 |
Why?
|
Feasibility Studies | 3 | 2018 | 5314 | 0.040 |
Why?
|
Chronic Disease | 2 | 2011 | 9384 | 0.040 |
Why?
|
Primary Health Care | 2 | 2012 | 4746 | 0.040 |
Why?
|
Developed Countries | 2 | 2012 | 454 | 0.040 |
Why?
|
Molecular Typing | 1 | 2017 | 115 | 0.030 |
Why?
|
Risk Reduction Behavior | 2 | 2014 | 1119 | 0.030 |
Why?
|
Universal Precautions | 1 | 2015 | 34 | 0.030 |
Why?
|
Genetic Testing | 1 | 2008 | 3589 | 0.030 |
Why?
|
Financing, Personal | 1 | 2017 | 310 | 0.030 |
Why?
|
Algorithms | 2 | 2017 | 14163 | 0.030 |
Why?
|
Poverty | 1 | 2006 | 2720 | 0.030 |
Why?
|
Obesity | 2 | 2021 | 13091 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2016 | 426 | 0.030 |
Why?
|
Internationality | 1 | 2020 | 1008 | 0.030 |
Why?
|
Blood Circulation | 1 | 2015 | 248 | 0.030 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2006 | 2165 | 0.030 |
Why?
|
Mycobacterium Infections | 2 | 2006 | 122 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 91 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3437 | 0.030 |
Why?
|
Sex Distribution | 2 | 2011 | 2276 | 0.030 |
Why?
|
Minority Groups | 1 | 2021 | 1217 | 0.030 |
Why?
|
Decision Making | 1 | 2007 | 3952 | 0.030 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2014 | 113 | 0.030 |
Why?
|
Follow-Up Studies | 5 | 2015 | 39345 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2021 | 1179 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 1996 | 541 | 0.030 |
Why?
|
Caregivers | 2 | 2017 | 2302 | 0.030 |
Why?
|
Harm Reduction | 1 | 2014 | 143 | 0.030 |
Why?
|
Streptomycin | 1 | 2012 | 69 | 0.030 |
Why?
|
Kanamycin | 1 | 2012 | 63 | 0.030 |
Why?
|
Depression | 1 | 2012 | 8231 | 0.030 |
Why?
|
Heterosexuality | 1 | 2014 | 309 | 0.020 |
Why?
|
Nose | 1 | 2015 | 522 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15660 | 0.020 |
Why?
|
Communication | 2 | 2020 | 3904 | 0.020 |
Why?
|
Mycoses | 2 | 2006 | 386 | 0.020 |
Why?
|
Thailand | 1 | 2012 | 288 | 0.020 |
Why?
|
Hospitals, Rural | 1 | 2012 | 174 | 0.020 |
Why?
|
Stereotyping | 1 | 2012 | 241 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2012 | 299 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3210 | 0.020 |
Why?
|
Cost of Illness | 2 | 2013 | 1951 | 0.020 |
Why?
|
Unsafe Sex | 1 | 2012 | 239 | 0.020 |
Why?
|
Abdomen | 1 | 1996 | 1137 | 0.020 |
Why?
|
Eosinophils | 1 | 2015 | 951 | 0.020 |
Why?
|
Rifampin | 1 | 2012 | 352 | 0.020 |
Why?
|
Stavudine | 1 | 2010 | 85 | 0.020 |
Why?
|
Carbon Dioxide | 1 | 2014 | 1148 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2010 | 152 | 0.020 |
Why?
|
Public Assistance | 1 | 2009 | 47 | 0.020 |
Why?
|
Sexual Partners | 1 | 2014 | 805 | 0.020 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2009 | 30 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2021 | 1885 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4258 | 0.020 |
Why?
|
Consent Forms | 1 | 2009 | 55 | 0.020 |
Why?
|
Cell Count | 1 | 2013 | 1831 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12536 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3701 | 0.020 |
Why?
|
Policy | 1 | 2012 | 513 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2010 | 286 | 0.020 |
Why?
|
Melanoma | 1 | 2007 | 5706 | 0.020 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5887 | 0.020 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2012 | 591 | 0.020 |
Why?
|
Hemoglobins, Abnormal | 1 | 2008 | 119 | 0.020 |
Why?
|
Respiration | 1 | 2014 | 1661 | 0.020 |
Why?
|
Environment | 1 | 2014 | 1121 | 0.020 |
Why?
|
National Health Programs | 1 | 2011 | 442 | 0.020 |
Why?
|
Mandatory Reporting | 1 | 2008 | 123 | 0.020 |
Why?
|
Meningitis, Cryptococcal | 1 | 2008 | 67 | 0.020 |
Why?
|
Pediatrics | 2 | 2013 | 3629 | 0.020 |
Why?
|
Workplace | 1 | 2014 | 873 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2007 | 5861 | 0.020 |
Why?
|
Social Support | 1 | 2017 | 2193 | 0.020 |
Why?
|
Direct Service Costs | 1 | 2006 | 61 | 0.020 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 2006 | 19 | 0.020 |
Why?
|
Bacterial Infections | 2 | 2006 | 1397 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 1080 | 0.020 |
Why?
|
Focus Groups | 1 | 2012 | 1460 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1596 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2358 | 0.020 |
Why?
|
China | 1 | 2012 | 2395 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2010 | 1478 | 0.020 |
Why?
|
Microscopy | 1 | 2010 | 909 | 0.020 |
Why?
|
Candidiasis | 1 | 2008 | 367 | 0.020 |
Why?
|
Schools | 1 | 2014 | 1498 | 0.020 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2006 | 211 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2006 | 435 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5955 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 878 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2008 | 682 | 0.010 |
Why?
|
Federal Government | 1 | 2006 | 266 | 0.010 |
Why?
|
Review Literature as Topic | 1 | 2006 | 297 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2010 | 2923 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3966 | 0.010 |
Why?
|
Comorbidity | 2 | 2011 | 10590 | 0.010 |
Why?
|
Muscle Weakness | 1 | 2006 | 412 | 0.010 |
Why?
|
Arm | 1 | 2006 | 591 | 0.010 |
Why?
|
Diet | 1 | 2021 | 8087 | 0.010 |
Why?
|
Awards and Prizes | 1 | 2008 | 365 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2336 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8540 | 0.010 |
Why?
|
Contrast Media | 1 | 1996 | 5330 | 0.010 |
Why?
|
Markov Chains | 1 | 2007 | 979 | 0.010 |
Why?
|
Animals | 3 | 2021 | 169222 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2009 | 1443 | 0.010 |
Why?
|
Parasitic Diseases | 1 | 2003 | 76 | 0.010 |
Why?
|
Siblings | 1 | 2007 | 828 | 0.010 |
Why?
|
Medication Adherence | 1 | 2014 | 2187 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2008 | 2357 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2006 | 1836 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3773 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 1736 | 0.010 |
Why?
|
Schools, Medical | 1 | 2008 | 882 | 0.010 |
Why?
|
Disabled Persons | 1 | 2010 | 1210 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 2972 | 0.010 |
Why?
|
Brain | 1 | 2006 | 27366 | 0.010 |
Why?
|
Pain | 1 | 2013 | 5100 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2001 | 1527 | 0.010 |
Why?
|
Malaria | 1 | 2006 | 1249 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2006 | 36742 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14783 | 0.010 |
Why?
|
Seizures | 1 | 2006 | 2998 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 13053 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 1996 | 20757 | 0.010 |
Why?
|
Prognosis | 1 | 2012 | 29979 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2001 | 4564 | 0.010 |
Why?
|
Mutation | 1 | 2009 | 30211 | 0.000 |
Why?
|